复方嗜酸乳杆菌片联合马来酸曲美布汀治疗腹泻型肠易激综合征患者的效果

目的 探究复方嗜酸乳杆菌片联合马来酸曲美布汀治疗腹泻型肠易激综合征患者的效果。方法 选取103例腹泻型肠易激综合征患者作为研究对象,随机将其分为对照组(51例)和观察组(52例)。对照组行马来酸曲美布汀片治疗,观察组在对照组基础上行复方嗜酸乳杆菌片治疗。比较两组患者临床疗效,腹痛、腹泻评分,胃肠相关激素水平,以及肠道菌群数量和不良反应发生情况。结果 治疗1个月后,观察组治疗总有效率、乳杆菌菌群数量均高于对照组,腹痛评分、腹泻评分、5-羟色胺水平、神经肽Y水平、生长抑素水平、肠球菌菌群数量、酵母样真菌菌群数量均低于对照组(均P<0.05)。两组不良反应发生情况差异无统计学意义(P>0.05)。结论 复方嗜酸乳杆菌联合马来酸曲美布汀可以有效地改善腹泻型肠易激综合征患者的症状,调节胃肠相关激素,促进肠道菌群平衡,安全性较高。     

益生菌饮料真的可以帮助消化吗?

正市场上的益生菌产品各种各样,不少都宣称能够"调节肠道细菌"、"改善消化不良",让不少长期久坐、缺乏运动的白领心动不已。不过,益生菌真的有改善肠道问题,帮助消化的功能吗?益生菌可以通过改善宿主肠道菌群平衡对宿主发挥有益作用,包括乳双歧杆菌、嗜酸乳杆菌、干酪乳杆菌、嗜热链球菌等。     

益生菌饮料真的可以帮助消化吗?

正市场上的益生菌产品各种各样,不少都宣称能够"调节肠道细菌"、"改善消化不良",让不少长期久坐、缺乏运动的白领心动不已。不过,益生菌真的有改善肠道问题,帮助消化的功能吗?益生菌可以通过改善宿主肠道菌群平衡对宿主发挥有益作用,包括乳双歧杆菌、嗜酸乳杆菌、干酪乳杆菌、嗜热链球菌等。不过,如果希望益生菌能够在人体内发     

2型糖尿病并发脑梗死患者血脂水平的变化

目的 观察2型糖尿病并发脑梗死(cerebral infarction,CI)患者的血糖、血脂水平.方法 将48例2型糖尿病并发CI患者,68例2型糖尿病患者与78例正常人对照,分别测空腹血糖(FPG)、三酰甘油(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C).结果 2型糖尿病合并CI患者的血糖、血脂水平均较正常对照组明显增高(P<0.05);并发CI组患者的血糖、低密度脂蛋白-胆固醇较未合并CI的糖尿病组也明显增高(P<0.05).结论 糖尿病患者糖代谢紊乱,血脂异常可能是其易发生CI的主要因素.     

利拉鲁肽对2型糖尿病患者肠道菌群及血糖血脂的影响北大核心CSCD

目的探究利拉鲁肽对2型糖尿病患者肠道菌群及血糖血脂的影响。方法选取2020年3月-2021年3月在本院治疗的2型糖尿病患者112例,随机分为观察组和对照组,每组56例。观察组皮下注射利拉鲁肽0.6 mg/次,1次/d。在空腹血糖高于7.8 mmol/L、餐后2 h血糖超过11.1 mmol/L的情况下,皮下注射利拉鲁肽1.2 mg/次,1次/d。对照组口服二甲双胍0.5 g/次,3次/d。两组均治疗16周。治疗结束后检测血低密度脂蛋白(LDL)、甘油三酯(TC)、高密度脂蛋白(HDL)、总胆固醇(TG)及餐后2 h血糖。采用ELISA检测炎性因子IL-10、IL-4、TNF-α和IL-1β。收集患者治疗前后新鲜粪便,提取总DNA,PCR扩增16srDNA V3高变区并进行Illumina二代高通量测序,分析肠道菌群多样性。结果治疗16周,对照组和观察组患者空腹血糖FPG分别为(9.64±1.23)mmol/L和(7.38±1.26)mmol/L,差异有统计学意义(均P<0.01);餐后2 h血糖分别为(15.24±2.17)mmol/L和(13.85±1.54)mmol/L,差异有统计学意义(均P<0.01);糖化血红蛋白(HbA1C),LDL及TG含量组间比较差异均有统计学意义(均P<0.01);TC及HDL含量差异均无统计学意义。观察组患者血TNF-α由(24.83±2.53)ng/L降至(14.49±1.38)ng/L,与对照组比较差异有统计学意义(t=4.6450,P=0.0002)。IL-1β由(5.58±0.52)ng/L降至(2.41±0.21)ng/L,与对照组比较差异有统计学意义(t=3.624,P=0.0018)。观察组患者肠道菌群丰度以及多样性与对照组比较差异均有统计学意义(均P<0.05),且双歧杆菌科、乳酸杆菌科丰度与患者空腹血糖浓度呈负相关(P=0.001和P=0.031),双歧杆菌科丰度与患者血液TNF-α含量成负相关(P=0.006)。结论利拉鲁肽在一定程度上能够改善2型糖尿病患者糖脂水平,提高肠道益生菌数量和相对丰度,改善炎症状态。     

嗜酸乳杆菌联合莫沙必利治疗颅脑损伤术后胃肠功能障碍的临床研究

背景 重型颅脑损伤后多数患者存在胃肠动力不足现象,当机体受到外界机械创伤时,易引发感染、呕吐、胃内容物反流等现象,使早期胃肠功能出现障碍,影响营养摄入,加重脑水肿,延迟伤口愈合,不利于患者预后.莫沙必利为临床常用促胃肠动力药,可提升胃肠道动力,加快胃排空.同时,嗜酸乳杆菌可调节肠道内菌群,保护肠道黏膜屏障、维持肠道平衡状态、缓解胃动力.本研究旨在探讨嗜酸乳杆菌联合莫沙必利治疗对颅脑损伤术后胃肠功能障碍患者肠内营养达标时间、肠道菌群、康复进程等方面的影响,分析其临床应用效果.目的 观察嗜酸乳杆菌联合莫沙必利治疗颅脑损伤术后胃肠功能障碍临床效果.方法 选取2018-02/2021-02我院颅脑损伤术后胃肠功能障碍患者92例,以随机数字表法按1:1比例分为研究组、对照组,各46例.常规治疗基础上,对照组予以莫沙必利,研究组予以嗜酸乳杆菌联合莫沙必利,均治疗1wk.比较两组临床疗效、肠内营养达标时间、康复进程、28 d病死率以及治疗前、治疗3 d、1 wk后胃动力指标[腹内压(intra-abdominal pressure, IAP)、胃残留量(gastric residual volume, GRA)]、肠道屏障功能指标[D-乳酸(D-lactic acid, D-LA)、二胺氧化酶(diamine oxidase, DAO)]水平、肠道菌群(双歧杆菌、乳酸杆菌、肠球菌、肠杆菌)数量.结果 研究组总有效率93.48%较对照组78.26%高(P0.05);研究组肠内营养达标时间、机械通气时间、重症监护病房住院时间较对照组短(P 0.05);两组28d病死率相比,差异无统计学意义;研究组治疗3 d、1wk后IAP、GRA及D-LA、DAO水平均低于对照组(P 0.05);研究组治疗3d、1wk后双歧杆菌、乳酸杆菌数量均多于对照组,肠球菌、肠杆菌数量均少于对照组(P0.05).结论 嗜酸乳杆菌联合莫沙必利治疗颅脑损伤术后胃肠功能障碍疗效显著,可缩短肠内营养达标时间,调节肠道菌群,保护肠黏膜屏障,促进胃肠道功能恢复,加快患者康复进程.     

薯蓣粥对2型糖尿病肠道内双歧杆菌及血糖影响研究

目的探讨薯蓣粥对2型糖尿病患者肠道内双歧杆菌及血糖的影响,从肠道菌群的角度为糖尿病的防治提供新的干预靶点。方法根据纳入和排除标准,纳入2015年4月至10月福建省立医院糖尿病健康教育俱乐部的2型糖尿病患者90例,随机分为试验组和对照组各45例。对照组给予健康教育与门诊随访,试验组在此基础上每天早上服用薯蓣粥1次,连续干预12周。对两组患者干预前后肠道内双歧杆菌、血糖运用方案数据分析(per-protocol population,PP)和意向性分析(Intention to treat,ITT)法进行分析。结果组间PP和ITT比较分析显示:试验组肠道内青春双歧杆菌、婴儿双歧杆菌数量均高于对照组,试验组空腹血糖、早餐后2 h血糖均低于对照组,差异有统计学意义(P0.05);ITT分析显示:试验组双歧杆菌总菌量高于对照组,差异有统计学意义(P0.05)。结论本研究显示,薯蓣粥具有调节2型糖尿病患者肠道内双歧杆菌生长、降低空腹血糖和早餐后2 h血糖的作用,降糖作用和肠道内双歧杆菌的关系还有待进一步揭示。     

不同性别2型糖尿病患者血脂、血压与骨质疏松的关系

目的以绝经后女性2型糖尿病患者为研究对象,与同年龄段的男性2型糖尿病患者作比较,探讨不同性别的2型糖尿病患者血脂、血压及血糖与骨质疏松关系的影响。方法入选2010-04-2011-07在福建医科大学附属第一医院住院的2型糖尿病患者182例,以无糖代谢异常的64例患者作为对照组。采用双能X线吸收法测量骨密度,使用OLYMPUS2700全自动生化分析仪测定血脂和血糖,根据骨密度的T值将2型糖尿病患者再分为骨质疏松组及非骨质疏松组,比较不同性别骨质疏松组和非骨质疏松组间的血脂、血压、血糖及骨密度的差异。对不同性别的2型糖尿病患者和对照组分别进行Pearson相关分析及Logistic回归分析,比较不同性别糖尿病患者的骨密度、骨质疏松与血糖、血脂、血压的关系。结果不同性别的2型糖尿病和同性别的对照组患者比较,双股骨骨密度、腰椎1～4骨密度的差异无统计学意义(P>0.05),对照组男女性别两组的血糖、血脂和血压与骨质疏松及骨密度无相关关系(P>0.05)。女性2型糖尿病骨质疏松组较非骨质疏松组的总胆固醇[(5.43±1.32)比(4.49±0.90)mmol/L]、低密度脂蛋白胆固醇(LDL-C)[(3.39±1.16)比(2.60±0.73)mmol/L]高(均P<0.05),女性2型糖尿病双股骨骨密度与总胆固醇、LDL-C呈负相关(分别r=-0.332,-0.263,均P<0.05),腰椎1～4骨密度与总胆固醇、三酰甘油、LDL-C呈负相关(分别r=-0.314,-0.319,-0.249,均P<0.05)。男性2型糖尿病的血脂、血压和血糖与骨密度无相关性(P>0.05)。Logistic回归分析表明总胆固醇是绝经后女性2型糖尿病女性骨质疏松的影响因素(OR=1.28,P<0.05)。结论 2型糖尿病绝经后女性的血脂与骨密度、骨质疏松存在着相关关系,男性的血脂、血压与骨质疏松无相关性。     

复方嗜酸乳杆菌联合匹维溴铵治疗腹泻型肠易激综合征效果观察

目的观察复方嗜酸乳杆菌联合匹维溴铵治疗腹泻型肠易激综合征的临床疗效。方法选取2013年10月至2017年9月确诊为腹泻型肠易激综合征的176例患者,随机分为对照组和治疗组,各88例。对照组患者口服匹维溴铵片3次/d,50 mg/次。治疗组患者在对照组用药基础上,增加口服复方嗜酸乳杆菌片3次/d,1.0 g/次。对照组及治疗组均连续治疗4周后进行门诊随访,记录治疗前后腹胀、腹泻、腹痛等腹部不适以及日排便次数、排便急迫天数以及焦虑抑郁评分的变化。结果经复方嗜酸乳杆菌联合匹维溴铵治疗后,治疗组患者日排便次数、排便急迫天数及腹部不适评分均明显下降(P0.001),且治疗组以上指标均明显低于对照组(P0.001)。治疗组总有效率为84.09%,明显高于对照组的68.18%(P0.05)。治疗后,治疗组HAMA评分(14.55±2.14)分、HAMD评分(15.23±2.99)分,显著低于对照组的HAMA评分(19.11±2.76)分、HAMD评分(19.81±3.62)分(P均0.05)。结论复方嗜酸乳杆菌联合匹维溴铵治疗腹泻性肠易激综合症,能够有效地缓解腹痛、腹泻、腹部不适症状,改善肠道功能,改善患者精神状态,值得临床进一步研究应用。     

四联疗法及嗜酸乳杆菌在幽门螺杆菌根除治疗中的疗效评估

目的评估四联疗法及嗜酸乳杆菌在幽门螺杆菌(H.pylori)根除治疗中的疗效。方法 120例消化性溃疡或慢性胃炎H.pylori感染患者,随机分为4组:三联组(兰索拉唑30 mg,2次/d+克拉霉素缓释片0.5 g,2次/d+阿莫西林1.0 g,2次/d)、三联组+嗜酸乳杆菌(三联组+复方嗜酸乳杆菌片1.0 g,3次/d)、四联组(兰索拉唑30 mg,2次/d+克拉霉素缓释片0.5 g,2次/d+阿莫西林1.0 g,2次/d+枸橼酸铋钾胶囊220 mg,2次/d)、四联组+嗜酸乳杆菌(四联组+复方嗜酸乳杆菌片1.0 g,3次/d)。PPI及铋剂为早晚餐前半小时服用,抗生素为早晚餐后即服,嗜酸乳杆菌服用时间需与抗生素间隔2 h以上,3次/d,疗程均为10 d。治疗结束4周后行14C-尿素呼气试验,阴性者判断为H.pylori根除。随诊并记录患者药物不良反应,了解患者依从性和耐受性,并同步对其成本及效果进行分析。结果 4组患者的根除率分别为63.3%、88.9%、90.3%、90.6%。与三联组相比,其他3组根除率显著升高,差异有统计学意义(P<0.05)。与不含嗜酸乳杆菌组相比,含嗜酸乳杆菌组不良反应发生率明显减少(P<0.05)。4组方案中以四联组成本-效果比最低(5.88),三联组最高(8.04)。结论含铋剂四联方案H.pylori根除率显著高于标准三联方案成本效果比最低;嗜酸乳杆菌能显著降低抗生素相关副作用的发生率。     

阿司匹林对2型糖尿病患者血清可溶性CD40配体水平的影响

目的观察2型糖尿病（T2DM）患者血清可溶性CD40配体（sCD40L）水平的变化，以及阿司匹林（ASP）对其水平的影响。方法T2DM患者55例按是否服用阿司匹林（ASP）分为DM不服用ASP（DMwithoutASP）组24例和DM服用ASP组（DMwithASP）31例，设对照组33例。采用ELISA法测定血清sCD40L水平。结果DM-ASP组较对照组的sCD40L水平升高（2．14±0．74VS1．89±1．07，P〉0．05），DM＋ASP组CD40L较DM组下降（1．19±0．76，P〈0．01），较对照组下降（P〈0．01）。结论DM患者血清sCD40L升高；服用ASP可降低DM患者sCD40L水平。     

Association between plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and lipids with rs7903146 polymorphisms of the TCF7L2 gene in diabetic patients

The rs7903146 polymorphism of TCF7L2 gene is known as the strongest genetic risk factor for type 2 diabetes mellitus (T2DM). The polymorphism is in association with clinical profile of T2DM patients. PCSK9 is a serine protease that promotes LDLR degradation and regulates circulating levels of lipids. The association of this polymorphism with PCSK9 and metabolic profile of diabetic and healthy subjects was investigated. This cross-sectional study was performed on 132 T2DM patients and the same number of healthy subjects. All the participants were genotyped for the rs7903146 single nucleotide polymorphism by the PCR-RFLP method. Metabolic profile including plasma levels of PCSK9, triglycerides, total cholesterol, non-HDL cholesterol, LDL cholesterol, HDL cholesterol, fasting plasma glucose, and HBA1C was measured. PCSK9, total cholesterol, and LDL-C levels were lower in the diabetic patients as compared to the healthy subjects. There were also direct and significant associations between PCSK9 and TG, TC, LDL-C, and non HDL-C in the subjects. Values of plasma glucose, HbA1c, PCSK9, TC, and LDL-C were higher in patients with TT genotype, but the differences were not statistically significant for all. A positive Spearman correlation was found between PCSK9 levels and the genotypes in all the participants. The results confirm the association of rs7903146 in the TCF7L2 gene with metabolic parameters and PCSK9. The T allele was associated with higher lipid and PCSK9 levels.

     

2型糖尿病正常糖耐量一级亲属血清可溶性CD40配体水平及其相关因素分析

目的本文旨在观察2型糖尿病（T2DM）患者正常糖耐量一级亲属（FDR）血清可溶性CD40配体（sCD40L）水平的变化,并分析相关影响因素。方法在41个T2DM家系中收集糖耐量正常的FDR26名,同时设T2DM患者24例（T2DM组）,健康者21名作为对照（Con组）。采用ELISA法测定血清sCD40L水平。结果NGT-FDR组的sCD40L水平较对照组升高（1．88±0．47vs1．63±0．58,P=0．182）,T2DM组sCD40L水平显著升高（2．14±0．75,P=0．043vsCon组）。sCD40L水平与空腹血糖呈正相关（r=0．325,P=0．006）。结论T2DM患者血清sCD40L明显高于糖耐量正常者;T2DM患者正常糖耐量一级亲属血清sCD40L水平已呈升高趋势;sCD40L水平与空腹血糖水平呈正相关。我们推测sCD40L升高在T2DM自然病程中可能发挥一定作用。     

A comparative study of the clinical profile of fibrocalculous pancreatic diabetes and type 2 diabetes mellitus

AimsThe present study aimed to compare the clinical characteristics of patients with fibrocalculous pancreatic diabetes (FCPD) and those with type 2 diabetes mellitus (T2DM) to identify the characteristics distinctive of FCPD.MethodsA total of 133 patients with FCPD were compared with 665 patients with T2DM matched for duration of diabetes. Biochemical parameters and microvascular and macrovascular complications were assessed in all patients. Multivariate regression analyses were performed to study the determinants of microvascular and macrovascular complications in both groups.ResultsThe mean duration of diabetes was 4.42 ± 5.65 years in the FCPD group and 4.51 ± 3.88 years in the T2DM group. FCPD participants were significantly younger at diagnosis and leaner than patients with T2DM. The FCPD group had higher fasting and postprandial glucose and HbA1c levels than the T2DM group. The FCPD group had significantly lower triglyceride, total cholesterol, low-density lipoprotein cholesterol, serum total calcium, hemoglobin, and serum creatinine values than the T2DM group. The prevalence of coronary artery disease, stroke, and retinopathy was significantly higher in the T2DM patients while the prevalence of distal symmetric polyneuropathy was significantly lower. On multivariate logistic regression analysis, duration of diabetes and HbA1c (OR = 1.17, P = 0 0.04) in FCPD patients and age (OR = 1.04, P < 0 0.001), duration of diabetes (OR = 1.17, P < 0 0.001) and HbA1c (OR = 1.28, P < 0.001) in T2DM patients were associated with microvascular complications.ConclusionsThere are several differences in the phenotype, biochemical parameters, and prevalence of diabetic complications between patients with FCPD and T2DM. Timely diagnosis may have implications in the follow-up and management of patients.     

Relationship between type 2 diabetes mellitus and a novel polymorphism C698T in C5L2 in the Chinese Han population

In a previous study, we reported a novel single nucleotide polymorphism (SNP) 698C>T (P233L) in the gene, C5L2. This gene has been demonstrated to encode a functional receptor of acylation-stimulating protein (ASP), a G-protein-coupled receptor (GPCR), that has been shown to influence insulin secretion in cultured pancreatic islet cells in vitro and is a stimulator of triglyceride synthesis and glucose transport in vivo. In this study, we evaluated the relationship between this novel C5L2 SNP and development of type 2 diabetes mellitus (T2DM) in the Chinese Han population. A case-control study examining Chinese Han T2DM patients (n?=?554) and healthy controls (n?=?648) was performed to investigate the role of the 698C>T (P233L) C5L2 polymorphism. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis was used to determine expression of this SNP. Heterozygote carriers of the 698CT C5L2 genotype were more frequent among T2DM patients (13.5%) than controls (3.2%; P?相似文献   

Plasma glucagon decreases during night-time sleep in Type 1 diabetic patients and healthy control subjects.

AIMS: In Type 1 diabetes mellitus (T1DM), the glucagon response to hypoglycaemia is known to disappear within a few months after the onset of the disease, whereas the response to other stimuli remains intact. The dynamics of spontaneous glucagon release have rarely been assessed. We monitored spontaneous glucagon release in T1DM patients and healthy subjects during a 7-h period of night-time sleep. METHODS: Measurements were made in 14 T1DM patients and 14 control subjects matched for age, gender and body mass index after one night's adaptation in our laboratory. Circulating glucose, insulin and glucagon concentrations were measured at 30-min intervals. In diabetic patients, hypoglycaemia (< 3.9 mmol/l) was avoided by infusion of glucose whenever necessary. RESULTS: During the entire night, plasma glucose and serum insulin levels were higher in T1DM patients than in healthy subjects (P < 0.03 and P < 0.001, respectively). Plasma glucagon concentrations decreased throughout the night in both groups (P < 0.001). Glucagon levels were similar in T1DM patients and healthy subjects (P > 0.87). The duration of diabetes (less and more than 5 years) did not affect glucagon secretion (P > 0.87). CONCLUSIONS: Plasma glucagon levels decrease significantly during night-time sleep in healthy control subjects. This nocturnal decrease is preserved in T1DM patients regardless of the duration of diabetes. These observations point to distinct nocturnal regulation of spontaneous glucagon release that does not depend on circulating glucose and insulin levels and is unaltered in T1DM patients.     

Impact of family history of diabetes and ethnicity on -cell function in obese, glucose-tolerant individuals

CONTEXT: The increased insulin secretion in response to reduced insulin sensitivity (SI) is heritable, but whether the genetic predisposition is restricted to members of high-risk Caucasian families is unknown. Furthermore, the relative importance of insulin resistance and defective beta-cell compensation in the increased prevalence of type 2 diabetes (T2DM) in African-American compared with Caucasian individuals is uncertain. OBJECTIVES: We tested whether obese individuals with a family history of T2DM have decreased beta-cell compensation compared with obese controls without a family history of T2DM. In addition, we compared S(I) and insulin secretion measures in African-American and Caucasian individuals. DESIGN: SI, acute insulin response to iv glucose (AIRg), maximally potentiated insulin response to arginine (AIRmax), and disposition indexes (DIs) (DI = SI * AIRg; DImax = SI * AIRmax) were compared among nondiabetic Caucasian and African-American individuals with and without a family history of diabetes. SETTING: This study was performed in an Ambulatory General Clinical Research Center. Subjects: Subjects were healthy, nondiabetic individuals with or without a family history of T2DM. INTERVENTIONS: There were no interventions. MAIN OUTCOME MEASURES: Comparison of SI, AIRg, AIRmax, DI, and DImax between Caucasians and African-Americans with or without a strong family history of T2DM were made. RESULTS: Obese subjects did not differ in SI, AIRg, or DI by family history of diabetes. African-Americans had 8% lower SI (P < 0.001), but 68% higher AIRg (P < 0.001) and 46% higher DI (P = 0.001) than age, gender, body mass index-matched Caucasian individuals. However, African-Americans had lower DImax compared with Caucasians. CONCLUSIONS: We found no reduction in insulin secretion in obese subjects with a family history of T2DM compared with controls, but in general, African-Americans were more insulin resistant and had lower maximal beta-cell response (DImax). The paradoxical increased DI could be explained by the reduced hepatic insulin extraction.     

Upregulation of SCUBE2 expression in dyslipidemic type 2 diabetes mellitus is associated with endothelin-1

Type 2 diabetes mellitus (T2DM) is a major health problem for morbidity and mortality world-wide due to diabetic vascular complication. Following T2DM, dyslipidemia is known well for the main reason of vascular complication leading to atherosclerosis and impaired life expectancy in diabetes. Thus, a new prediction marker in T2DM could help prevent the progression disease despite of metabolic control. Signal peptide–CUB-EGF like containing protein 2 (SCUBE2), has been detected in vascular endothelium and was affected by cytokines. Recently, SCUBE2 was reported to increase in atherosclerotic human coronary artery, involving vascular smooth muscle cells (VSMCs) and macrophages. The aims of this study were to examine the expression level of SCUBE2 in T2DM patients with dyslipidemia and its correlation with endothelial dysfunction marker, endothelin-1 (ET-1) in this group. This study design was cross sectional control study, recruited 28 patients diagnosed as T2DM who were found with dyslipidemia and 15 healthy control subjects. Our results showed that T2DM patients showed higher LDL cholesterol, triglycerides, and ET-1 expression level compared to healthy subjects. Further, we found that SCUBE2 had strong correlation with ET-1 in these dyslipidemic T2DM patients. In conclusion, our study confirmed first that SCUBE2 was upregulated in T2DM with dyslipidemia. Moreover, Pearson correlation analysis of ET-1 and SCUBE2 in this group showed high correlation r = 0.797, P < 0.001, suggesting that SCUBE2 may plausible target in vascular function changes in dyslipidemic T2DM. Improving our exploration of these findings may lead to uncover SCUBE2 involvement in diabetic vascular complication in T2DM.     

代谢综合征患者过氧化物酶体增殖物激活受体δ+294T/C基因多态性与血脂、肥胖和左室肥厚的关系

目的探讨代谢综合征(MS)患者过氧化物酶体增殖物激活受体δ(PPARδ)+294T/C基因多态性与血脂、肥胖和左室肥厚的关系。方法检测300例MS、174例高血压病(EH)和143例2型糖尿病(DM)患者的体重指数(BMI)、腰围、血压、血脂、空腹血糖(FBG)和空腹血浆胰岛素(FINS)。MS诊断根据1999年WHO亚太诊断标准,其中389例患者行超声心动图检测心脏结构改变,应用聚合酶链反应-限制性片段长度多态性方法测定PPARδ+294T/C基因多态性。结果PPARδ+294T/C基因多态性各基因型频率分布组间比较差异无统计学意义。MS组血浆总胆固醇、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)水平和BMI明显高于DM组。MS组和EH组的左室重量(LVM)、左室重量指数(LVMI)和左室肥厚罹患率均明显高于DM组。MS组CC型血浆总胆固醇和LDL-C水平明显高于TT型和TC型[总胆固醇:CC型(6.13±1.86)mmol/L比TC型(5.14±1.10)mmol/L或TT型(4.99±1.42mmol/L),P<0.05或P<0.01;LDL-C:CC型(3.82±1.52)mmol/L比TC型(3.14±0.88)mmol/L或TT型(2.90±0.87)mmol/L,P<0.05或P<0.01]。分析PPARδ各基因型与LVMI和BMI的关系,发现MS组C等位基因携带者(CC+TC)LVMI和BMI明显高于TT型[LVMI:CC+TC(46±10)g/m2.7比TT(44±10)g/m2.7;BMI:CC+TC(26±3)kg/m2比TT(25±3)kg/m2,P<0·05]。结论MS患者PPARδ+294T/C基因多态性与肥胖和脂质紊乱关系密切,C等位基因携带者较TT基因型患者左室重构明显。     

Detection of VDR gene ApaI and TaqI polymorphisms in patients with type 2 diabetes mellitus using PCR-RFLP method in a Turkish population

Type 2 diabetes mellitus (T2DM) is by far the most common type of diabetes and is characterized by insulin resistance and altered insulin secretion. Some genes, such as the vitamin D receptor gene (VDR, NM_001017535; GI: 7421), involved in its metabolic pathway have been regarded as good candidates for T2DM. In this study, we investigated whether there was an association of VDR: g.59979G>T or c.1025-49G>T (ApaIG>T) and g.60058T>C or c.1056T>C (TaqIT>C) polymorphisms in the 3′ untranslated region of VDR with T2DM in a Turkish population. We collected blood samples from 241 individuals (72 patients with T2DM and 169 healthy individuals), and their DNA was isolated. Polymorphisms of the VDR were analyzed by DNA amplification with polymerase chain reaction and endonuclease digestion with ApaI and TaqI. Body mass index was higher in T2DM patients than in control individuals. However, the frequency of g.59979TT genotype in T2DM patients was not significantly increased compared to healthy subjects (37.5% vs. 36.1%, respectively). Although the VDR g.60058CC genotype in T2DM patients (19.4%) was higher than that in healthy individuals (11.2%), there was no significant difference. In the same way, there was no difference between the groups in allele frequencies. In conclusion, our study did not provide evidence for the association of two examined VDR polymorphisms with T2DM in a Turkish population.